|Mr. Mark J. Enyedy||Pres, CEO & Director||568.98k||N/A||1964|
|Mr. David B. Johnston||Exec. VP, CFO & Principal Accounting Officer||279.44k||N/A||1955|
|Dr. Richard J. Gregory||Exec. VP & Chief Scientific Officer||312.48k||N/A||1958|
|Dr. Anna Berkenblit||VP & Chief Medical Officer||269.23k||N/A||1970|
|Ms. Carol Hausner||Exec. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
ImmunoGen, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 4. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 5; Compensation: 3.